Parul U Gandhi1, Hanna K Gaggin2, Margaret M Redfield3, Horng H Chen3, Susanna R Stevens4, Kevin J Anstrom4, Marc J Semigran2, Peter Liu5, James L Januzzi6. 1. VA CT Healthcare System, West Haven, Connecticut; Yale University School of Medicine New Haven, Connecticut. 2. Massachusetts General Hospital, Boston, Massachusetts. 3. Mayo Clinic Rochester, Minnesota. 4. Duke Clinical Research Institute, Durham, North Carolina. 5. University of Ottawa Heart Institute, Ottawa, Ontario, Canada. 6. Massachusetts General Hospital, Boston, Massachusetts. Electronic address: jjanuzzi@partners.org.
Abstract
OBJECTIVES: This study sought to investigate relationships between insulin-like growth factor-binding protein-7 (IGFBP7) and parameters of diastolic function or functional capacity in patients with heart failure and preserved ejection fraction (HFpEF) who were randomized to receive sildenafil or placebo. BACKGROUND:IGFBP7 was previously found to be associated with diastolic function in heart failure with reduced ejection fraction, but it is unclear whether these associations are present in HFpEF. METHODS: At baseline and 24 weeks, IGFBP7, imaging studies, and peak oxygen consumption (Vo2max) were obtained and compared in 160 patients with HFpEF who were randomized to receive sildenafil or placebo. RESULTS: Patients with supramedian baseline IGFBP7 concentrations were older, had signs of systemic congestion and worse renal function, and had higher concentrations of prognostic heart failure biomarkers including amino-terminal pro-B-type natriuretic peptide (p < 0.05). Higher baseline IGFBP7 was modestly correlated with worse diastolic function: higher E velocity (Spearman correlation [ρ] = 0.40), E/E' (ρ = 0.40), left atrial volume index (ρ = 0.39), and estimated right ventricular systolic pressure (ρ = 0.41; all p < 0.001) and weakly correlated with transmitral E/A (ρ = 0.26; p = 0.006). Notably, change in IGFBP7 was significantly correlated with change in E, E/A, E/E', and right ventricular systolic pressure. Elevated baseline IGFBP7 was associated with lower baseline Vo2max (13.2 vs. 11.1 ml/min/kg; p < 0.001), and change in IGFBP7 was weakly inversely correlated with change in Vo2max (ρ = -0.19; p = 0.01). Subjects receiving sildenafil had a decrease in IGFBP7 over 24 weeks, in contrast to placebo-treated patients (median change in IGFBP7 -1.5 vs. +13.6 ng/ml; p < 0.001). CONCLUSIONS: In patients with HFpEF, IGFBP7 may be a novel biomarker of diastolic function and exercise capacity.
RCT Entities:
OBJECTIVES: This study sought to investigate relationships between insulin-like growth factor-binding protein-7 (IGFBP7) and parameters of diastolic function or functional capacity in patients with heart failure and preserved ejection fraction (HFpEF) who were randomized to receive sildenafil or placebo. BACKGROUND:IGFBP7 was previously found to be associated with diastolic function in heart failure with reduced ejection fraction, but it is unclear whether these associations are present in HFpEF. METHODS: At baseline and 24 weeks, IGFBP7, imaging studies, and peak oxygen consumption (Vo2max) were obtained and compared in 160 patients with HFpEF who were randomized to receive sildenafil or placebo. RESULTS:Patients with supramedian baseline IGFBP7 concentrations were older, had signs of systemic congestion and worse renal function, and had higher concentrations of prognostic heart failure biomarkers including amino-terminal pro-B-type natriuretic peptide (p < 0.05). Higher baseline IGFBP7 was modestly correlated with worse diastolic function: higher E velocity (Spearman correlation [ρ] = 0.40), E/E' (ρ = 0.40), left atrial volume index (ρ = 0.39), and estimated right ventricular systolic pressure (ρ = 0.41; all p < 0.001) and weakly correlated with transmitral E/A (ρ = 0.26; p = 0.006). Notably, change in IGFBP7 was significantly correlated with change in E, E/A, E/E', and right ventricular systolic pressure. Elevated baseline IGFBP7 was associated with lower baseline Vo2max (13.2 vs. 11.1 ml/min/kg; p < 0.001), and change in IGFBP7 was weakly inversely correlated with change in Vo2max (ρ = -0.19; p = 0.01). Subjects receiving sildenafil had a decrease in IGFBP7 over 24 weeks, in contrast to placebo-treated patients (median change in IGFBP7 -1.5 vs. +13.6 ng/ml; p < 0.001). CONCLUSIONS: In patients with HFpEF, IGFBP7 may be a novel biomarker of diastolic function and exercise capacity.
Authors: Henry Krum; Maros Elsik; Hans G Schneider; Agata Ptaszynska; Marion Black; Peter E Carson; Michel Komajda; Barry M Massie; Robert S McKelvie; John J McMurray; Michael R Zile; Inder S Anand Journal: Circ Heart Fail Date: 2011-07-12 Impact factor: 8.790
Authors: Sherif F Nagueh; Christopher P Appleton; Thierry C Gillebert; Paolo N Marino; Jae K Oh; Otto A Smiseth; Alan D Waggoner; Frank A Flachskampf; Patricia A Pellikka; Arturo Evangelista Journal: J Am Soc Echocardiogr Date: 2009-02 Impact factor: 5.251
Authors: R Sacha Bhatia; Jack V Tu; Douglas S Lee; Peter C Austin; Jiming Fang; Annick Haouzi; Yanyan Gong; Peter P Liu Journal: N Engl J Med Date: 2006-07-20 Impact factor: 91.245
Authors: Michel Komajda; Peter E Carson; Scott Hetzel; Robert McKelvie; John McMurray; Agata Ptaszynska; Michael R Zile; David Demets; Barry M Massie Journal: Circ Heart Fail Date: 2010-11-10 Impact factor: 8.790
Authors: Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald Journal: JAMA Date: 2013-03-27 Impact factor: 56.272
Authors: Parul U Gandhi; Hanna K Gaggin; Alex D Sheftel; Arianna M Belcher; Rory B Weiner; Aaron L Baggish; Shweta R Motiwala; Peter P Liu; James L Januzzi Journal: Am J Cardiol Date: 2014-08-27 Impact factor: 2.778
Authors: Rudolf A de Boer; Dirk J A Lok; Tiny Jaarsma; Peter van der Meer; Adriaan A Voors; Hans L Hillege; Dirk J van Veldhuisen Journal: Ann Med Date: 2010-12-28 Impact factor: 4.709
Authors: Kianoush Kashani; Ali Al-Khafaji; Thomas Ardiles; Antonio Artigas; Sean M Bagshaw; Max Bell; Azra Bihorac; Robert Birkhahn; Cynthia M Cely; Lakhmir S Chawla; Danielle L Davison; Thorsten Feldkamp; Lui G Forni; Michelle Ng Gong; Kyle J Gunnerson; Michael Haase; James Hackett; Patrick M Honore; Eric A J Hoste; Olivier Joannes-Boyau; Michael Joannidis; Patrick Kim; Jay L Koyner; Daniel T Laskowitz; Matthew E Lissauer; Gernot Marx; Peter A McCullough; Scott Mullaney; Marlies Ostermann; Thomas Rimmelé; Nathan I Shapiro; Andrew D Shaw; Jing Shi; Amy M Sprague; Jean-Louis Vincent; Christophe Vinsonneau; Ludwig Wagner; Michael G Walker; R Gentry Wilkerson; Kai Zacharowski; John A Kellum Journal: Crit Care Date: 2013-02-06 Impact factor: 9.097
Authors: Frank Kramer; Hani N Sabbah; James J Januzzi; Faiez Zannad; J Peter van Tintelen; Erik B Schelbert; Raymond J Kim; Hendrik Milting; Richardus Vonk; Brien Neudeck; Richard Clark; Klaus Witte; Wilfried Dinh; Burkert Pieske; Javed Butler; Mihai Gheorghiade Journal: Heart Fail Rev Date: 2017-05 Impact factor: 4.214
Authors: Hilde M Norum; Kaspar Broch; Annika E Michelsen; Ida G Lunde; Tove Lekva; Aurelija Abraityte; Christen P Dahl; Arnt E Fiane; Arne K Andreassen; Geir Christensen; Svend Aakhus; Pål Aukrust; Lars Gullestad; Thor Ueland Journal: J Cardiovasc Transl Res Date: 2017-05-04 Impact factor: 4.132
Authors: Sasha K Shillcutt; M Megan Chacon; Tara R Brakke; Ellen K Roberts; Thomas E Schulte; Nicholas Markin Journal: J Cardiothorac Vasc Anesth Date: 2017-08-30 Impact factor: 2.628
Authors: Michael S Sabbah; Ahmed U Fayyaz; Simon de Denus; G Michael Felker; Barry A Borlaug; Surendra Dasari; Rickey E Carter; Margaret M Redfield Journal: Circ Heart Fail Date: 2020-07-29 Impact factor: 8.790
Authors: Yasmina Bauer; Simon de Bernard; Peter Hickey; Karri Ballard; Jeremy Cruz; Peter Cornelisse; Harbajan Chadha-Boreham; Oliver Distler; Daniel Rosenberg; Martin Doelberg; Sebastien Roux; Oliver Nayler; Allan Lawrie Journal: Eur Respir J Date: 2021-06-24 Impact factor: 16.671
Authors: Eva van den Bosch; Sjoerd S M Bossers; Vivian P Kamphuis; Eric Boersma; Jolien W Roos-Hesselink; Johannes M P J Breur; Arend D J Ten Harkel; Livia Kapusta; Beatrijs Bartelds; Arno A W Roest; Irene M Kuipers; Nico A Blom; Laurens P Koopman; Willem A Helbing Journal: J Am Heart Assoc Date: 2021-02-24 Impact factor: 5.501